Progression of pharmacology and clinical study of icotinib hydrochloride
WANG Lei
YU Peiyao
LIU Jiwei
Abstract：Non-small cell lung cancer ( NSCLC ) accounts for about 80%-85% of lung cancer. The main treatment of advanced NSCLC is medical treatment such as chemotherapy which shows poor efficacy. Recently, epidermal growth factor receptor-tyrosine kinase inhibitor ( EGFR-TKI) in the treatment of patients with advanced NSCLC has made a new breakthrough. Icotinib as a domestic EGFR-TKI, preclinical studies and clinical studies show that it has promising safety, tolerability and efficacy in patients with advanced NSCLC.
Keywords：Epidermal growth factor receptor-tyrosine kinase inhibitor( EGFR-TKI)Icotinib hydrochloridePharmaco-kineticsClinical trial
Publication Date：2014-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：6( 274-279 )